{"meta":{"query_hash":"f11415678379","filters":{"venue":"Rare Disease and Orphan Drugs Journal"},"cohort_total":4,"direct_labels_cover":0,"predictions_cover":4,"exported":4,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/f11415678379","api":"https://metacan.xera.ac/api/v1/cohort?venue=Rare+Disease+and+Orphan+Drugs+Journal"},"results":[{"id":"W4226226005","doi":"10.20517/rdodj.2022.01","title":"Enhancing the value of clinical networks for rare diseases","year":2022,"lang":"en","type":"article","venue":"Rare Disease and Orphan Drugs Journal","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Standards Association","funders":"","keywords":"Legitimacy; Health care; Knowledge management; Public relations; Diversity (politics); Best practice; Medicine; Political science; Computer science","score_opus":0.0097746278647512,"score_gpt":0.2818339027353585,"score_spread":0.2720592748706073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226226005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707542,0.025812326,0.0015576577,0.00033298647,0.0006951509,0.00028847618,0.00052540697,0.0000056074387,0.000028153381],"genre_scores_gemma":[0.996164,0.0012216257,0.00007724707,0.00083021465,0.0012025436,0.00004834923,0.00021593383,0.000025875404,0.00021417665],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986174,0.0002143772,0.00046748517,0.00026320797,0.00018597134,0.000251535],"domain_scores_gemma":[0.99889535,0.00010168197,0.00026407602,0.00025358205,0.00010572383,0.00037957268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047072335,0.00014776732,0.00021629434,0.000034007022,0.0006742442,0.000051324674,0.0002868055,0.00004017197,0.00006944229],"category_scores_gemma":[0.00018814417,0.000108926564,0.00042289565,0.00006276161,0.00010283721,0.0000063430957,0.00024923883,0.000159601,3.4128098e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035718694,0.006186965,0.38026494,0.001275464,0.006436344,0.0012275454,0.0022720427,0.05611706,0.023444327,0.006782143,0.29375684,0.18651763],"study_design_scores_gemma":[0.019880235,0.0045533027,0.33801684,0.00036905217,0.004838197,0.00096789555,0.017335115,0.01498212,0.00523399,0.011181796,0.57949036,0.0031510596],"about_ca_topic_score_codex":0.0000022638983,"about_ca_topic_score_gemma":0.0000014353782,"teacher_disagreement_score":0.28573352,"about_ca_system_score_codex":0.000009024033,"about_ca_system_score_gemma":0.00034735916,"threshold_uncertainty_score":0.518581},"labels":[],"label_agreement":null},{"id":"W4367019825","doi":"10.20517/rdodj.2023.04","title":"Sustainable approaches for drug repurposing in rare diseases: recommendations from the IRDiRC Task Force","year":2023,"lang":"en","type":"article","venue":"Rare Disease and Orphan Drugs Journal","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadiana.org","funders":"","keywords":"Repurposing; Drug repositioning; Identification (biology); Medicine; Sustainability; Task (project management); Task force; Drug development; Business; Drug; Pharmacology; Engineering; Political science","score_opus":0.04927013266708733,"score_gpt":0.33548942283619226,"score_spread":0.2862192901691049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367019825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7906239,0.058009744,0.00035493606,0.1467233,0.0005187741,0.002045252,0.00072127365,0.00013691928,0.00086591294],"genre_scores_gemma":[0.9853357,0.0073887086,0.00013584341,0.0025116904,0.0009121567,0.00014667754,0.00034132303,0.000034271678,0.0031936138],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986917,0.00014026581,0.00028543544,0.00024569224,0.00021226681,0.0004246795],"domain_scores_gemma":[0.99823713,0.00092007214,0.00012226558,0.000164181,0.00008967825,0.00046666415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050798594,0.00015458882,0.00023331222,0.0000820967,0.00085541134,0.00019963036,0.00011654905,0.000029205663,0.00011423372],"category_scores_gemma":[0.0005990209,0.00010273751,0.00015106006,0.0003186429,0.00006649233,0.00038634462,0.00011559811,0.0002882487,0.000007218349],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008064575,0.001064036,0.119218074,0.0013029772,0.0016073833,0.0027218086,0.02318806,0.00017567916,0.00008609577,0.002964229,0.5905741,0.24903299],"study_design_scores_gemma":[0.007251749,0.00011198129,0.07068246,0.0007767838,0.0020375447,0.000072150535,0.12554306,0.008273127,0.000052331132,0.02650307,0.75818646,0.00050928607],"about_ca_topic_score_codex":0.000044173892,"about_ca_topic_score_gemma":0.000010139516,"teacher_disagreement_score":0.24852371,"about_ca_system_score_codex":0.00007593494,"about_ca_system_score_gemma":0.00015634981,"threshold_uncertainty_score":0.65792185},"labels":[],"label_agreement":null},{"id":"W4400098184","doi":"10.20517/rdodj.2024.14","title":"Longitudinal biomarker evaluation in Fabry disease patients receiving lentivirus-mediated gene therapy","year":2024,"lang":"en","type":"article","venue":"Rare Disease and Orphan Drugs Journal","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Fleurimont","funders":"","keywords":"Globotriaosylceramide; Fabry disease; Enzyme replacement therapy; Genetic enhancement; Medicine; Biomarker; Urine; Internal medicine; Alpha-galactosidase; Urology; Disease; Gastroenterology; Oncology; Gene; Biology","score_opus":0.036504650923119136,"score_gpt":0.3265417238837958,"score_spread":0.2900370729606767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400098184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95472074,0.04304892,0.000058610323,0.00092985603,0.0003553545,0.00063249527,0.000060737257,0.00004214621,0.00015114971],"genre_scores_gemma":[0.9947982,0.00419917,0.000015766444,0.0001958342,0.00024782168,0.000048608126,0.00026247225,0.000044561628,0.00018756273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973455,0.00027447278,0.00036516253,0.0004178108,0.0011693517,0.0004277168],"domain_scores_gemma":[0.9984292,0.000101600905,0.00006281454,0.00019090793,0.0002935589,0.00092191616],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007583462,0.0002282393,0.00023456958,0.00052995654,0.00017679067,0.00025257454,0.00010571546,0.00006127924,0.0009907923],"category_scores_gemma":[0.00041917313,0.00018182435,0.0001683086,0.00054364075,0.00008278225,0.00046902595,0.00005870144,0.00037566945,0.00006461741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024026595,0.0005776987,0.7624726,0.00018422144,0.00021119496,0.0018330428,0.0005949821,0.0000045843926,0.00042338858,0.000004444458,0.0021627916,0.22912835],"study_design_scores_gemma":[0.0044008736,0.00009793746,0.9855925,0.00067753484,0.00018806134,0.000026845635,0.00014275912,0.0071540237,0.00004094213,0.0003901898,0.0010672593,0.00022111762],"about_ca_topic_score_codex":0.000015543399,"about_ca_topic_score_gemma":0.000005724343,"teacher_disagreement_score":0.22890723,"about_ca_system_score_codex":0.00026771068,"about_ca_system_score_gemma":0.000715739,"threshold_uncertainty_score":0.99992245},"labels":[],"label_agreement":null},{"id":"W4400570519","doi":"10.20517/rdodj.2023.61","title":"Fabry nephropathy: a treatable cause of chronic kidney disease","year":2024,"lang":"en","type":"article","venue":"Rare Disease and Orphan Drugs Journal","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Globotriaosylceramide; Medicine; Fabry disease; Enzyme replacement therapy; Proteinuria; Albuminuria; Nephropathy; Kidney disease; Alpha-galactosidase; Internal medicine; Podocyte; Cardiomyopathy; Dialysis; Glomerular basement membrane; Kidney; Disease; Heart failure; Pathology; Urology; Endocrinology; Diabetes mellitus","score_opus":0.01343904179696902,"score_gpt":0.29033695014167454,"score_spread":0.2768979083447055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400570519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86707824,0.12530896,0.00032707653,0.0050994125,0.00040602483,0.000531094,0.0004166758,0.00010179187,0.00073074223],"genre_scores_gemma":[0.9906084,0.004571995,0.000026548225,0.00045627513,0.00076281436,0.000019471803,0.00009631762,0.000052273317,0.0034058946],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981812,0.00008495777,0.00032314713,0.0003241251,0.00064314937,0.0004434042],"domain_scores_gemma":[0.99693555,0.00005396432,0.00005804991,0.00029130554,0.00015589189,0.002505263],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000208496,0.00021956135,0.0003099228,0.0003117915,0.0001764163,0.00016711322,0.00012929057,0.00005045669,0.0015682962],"category_scores_gemma":[0.00023911621,0.00016947031,0.00024761437,0.00036360577,0.00015731303,0.0003559516,0.00008773889,0.00037446228,0.000067727604],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01266468,0.0036789903,0.19570391,0.01793583,0.0038205967,0.11169896,0.0050625335,0.000049071074,0.007104594,0.0023199318,0.34643993,0.29352096],"study_design_scores_gemma":[0.04184481,0.0044886186,0.26148224,0.028681977,0.016234884,0.0064578196,0.0054036896,0.054520454,0.004122951,0.0134541625,0.55928504,0.0040233415],"about_ca_topic_score_codex":0.000024379677,"about_ca_topic_score_gemma":0.0000018523745,"teacher_disagreement_score":0.2894976,"about_ca_system_score_codex":0.00019869616,"about_ca_system_score_gemma":0.0025608893,"threshold_uncertainty_score":0.9993444},"labels":[],"label_agreement":null}]}